Feb 13, 2026
Evaluation of drug sensitivity in patient-derived MTSs
- Zhe Zhao1
- 1CAS Key Laboratory of Nano-Bio Interface, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Jiangsu, 215123, China.
- MTS
Protocol Citation: Zhe Zhao 2026. Evaluation of drug sensitivity in patient-derived MTSs. protocols.io https://dx.doi.org/10.17504/protocols.io.rm7vze2yxvx1/v1
License: This is an open access protocol distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Protocol status: Working
We use this protocol and it's working
Created: February 13, 2026
Last Modified: February 13, 2026
Protocol Integer ID: 243174
Keywords: mts model for drug susceptibility testing, drug susceptibility testing, evaluation of drug sensitivity, drug sensitivity, derived mtss, mts model, mtss, mtss the detailed process, mt
Funders Acknowledgements:
National Natural Science Foundation of China
Grant ID: 82202345
Abstract
The detailed process of using the MTS model for drug susceptibility testing.
Materials
96-well plate, SG-Medium, Celltiter-Glo reagent (Vazyme), Synergy plate reader (BioTek)
Troubleshooting
Evaluation of drug sensitivity in patient-derived MTSs
Fifty collected MTSs were aliquoted into each well of a 96-well plate. Based on the SR_70% cutoff value for each individual chemotherapy drug and clinical chemotherapy regimens, the MTSs were treated with control vehicles, single chemotherapy drugs, or drug combinations (e.g., E-T: 0.1 µM Epirubicin + 10 nM Docetaxel; EC-T: 0.1 µM Epirubicin + 0.56 µM Palifosfamide + 10 nM Docetaxel; EC-THP: 0.1 µM Epirubicin + 0.56 µM Palifosfamide + 10 nM Docetaxel + 10 µg/mL Trastuzumab and Pertuzumab; TCbHP: 10 nM Docetaxel + 3.16 µM Carboplatin + 10 µg/mL Trastuzumab and Pertuzumab) in a volume of SG-Medium (50 µL).
After three days of incubation, 50 µL Celltiter-Glo reagent (Vazyme) was added to each well to test the MTS survival rate (_SR_). The MTSs were incubated at room temperature for 10 min, followed by acquiring viability readings using a Synergy plate reader (BioTek).